Sucampo Pharmaceuticals, Inc. 4
4 · Sucampo Pharmaceuticals, Inc. · Filed Mar 21, 2014
Insider Transaction Report
Form 4
Dolecek Gayle R
DirectorVP of Research & Development
Transactions
- Sale
Class A Common Stock
2014-03-18$8.03/sh−1,200$9,636→ 0 total - Exercise/Conversion
Class A Common Stock
2014-03-18$4.41/sh+1,200$5,292→ 1,200 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2014-03-18−1,200→ 313,367 totalExercise: $4.41From: 2013-05-02Exp: 2021-05-02→ Class A Common Stock (1,200 underlying)
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on June 13, 2013.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.07, inclusive. The reporting person undertakes to provide Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.